Crucell N.V. (CRXL) And DSM Announce PER.C6(R) Licensing And Service Agreement With Roche (RHHBY) For Protein Production
10/19/2005 5:12:44 PM
LEIDEN, The Netherlands, Feb. 16, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) and allied contract manufacturer DSM Biologics announced today that they have signed a PER.C6(R) research license agreement with Roche. This license agreement allows Roche to use the PER.C6(R) cell line for production of monoclonal antibody products as well as a specific undisclosed protein.Roche has selected PER.C6(R) for this particular protein because it believes PER.C6(R) possesses unique features capable of delivering the appropriate product quality. Further to this agreement, Crucell will work with Roche in creating a production clone for the specific protein.
comments powered by